ライフサイエンスコーパス: reflux

1 further damage, infection and vesicoureteral reflux.

2 ly milder conditions, such as vesicoureteral reflux.

3 ency but >50% reflux; or (d) nonpatent, 100% reflux.

4 ociated with exposure to cigarette smoke and reflux.

5 ucosal impedance (MI) as a marker of chronic reflux.

6 l as those with neurodevelopmental delay and reflux.

7 ccurately and reliably measure chronicity of reflux.

8 could predispose them to esophagopharyngeal reflux.

9 ne-pyridine activation in dichloromethane at reflux.

10 d in children with non-severe vesicoureteric reflux.

11 cough due to reflux, LPR, and asthma due to reflux.

12 ealth, home oxygen use, and gastroesophageal reflux.

13 ith a catalytic amount of anhydrous FeCl3 in refluxing 1,2-dichloroethane underwent tandem Conia-ene

14 ive sleep apnea (+1 point), gastroesophageal reflux (+1 point), and depression (+1 point) was predict

15 allergic rhinitis (62.4%), gastroesophageal reflux (42.1%), sinusitis (37.9%), nasal polyposis (30.2

16 time pH < 4) than impedance criteria (total reflux):[42 vs 22 % (p =0.02)].

17 scopically, 20/23 (87%) had macroscopic bile reflux (74% yellowish bile lakes, 13% greenish bile lake

18 were white (78%), and 375 had vesicoureteral reflux (78%).

19 In reactions conducted in refluxing acetic acid, however, the 3-(chloromethyl)coum

20 he belt was impaired esophageal clearance of refluxed acid (median values of 23.0 seconds without bel

21 s are exposed to lethal chemical injury from refluxed acid.

22 23 had acidic reflux, whereas 9 had combined reflux [acidic + weakly acidic reflux (WAR)].

23 Heating a toluene solution of 3a or 3b at reflux afforded the rearranged species ArSn(3-tricyclo[2

24 n of impaired clearance was that of rapid re-reflux after peristaltic clearance.

25 Esophagitis, whether caused by acid reflux, allergic responses, graft-versus-host disease, d

26 were 7 million diagnoses of gastroesophageal reflux and almost 4 million diagnoses of hemorrhoids in

27 as past medical history significant for acid reflux and Clostridium difficile colitis.

28 is associated with chronic gastroesophageal reflux and esophageal cancer.

29 e management of children with vesicoureteric reflux and give suggestions on how to navigate this diff

30 stomy in reducing macro and microscopic bile reflux and impact on dyspepsia related quality of life i

31 uid reflux events prevent esophagopharyngeal reflux and its complications, however, abnormal response

32 improvements in symptoms of gastroesophageal reflux and rhinitis, bronchial reversibility, and exhale

33 97 non-treatment-seeking volunteers based on reflux and smoking status.

34 on on the sphincter as the main deterrent to reflux and the hope that measurement of a low LES pressu

35 ne whether the symptoms are due to recurrent reflux and to understand what caused the recurrence.

36 acid by conventional extraction (CE), under reflux and ultrasound assisted extraction (UAE) at 37 kH

37 n 4 on pH monitoring and/or gastroesophageal reflux and/or herniated wrap on upper gastrointestinal (

38 ugh substrate, which suppresses hot electron refluxing and thus alleviates plasma heating.

39 , including lymphangiectasia, chylolymphatic reflux, and chylous leak.

40 The severity of diarrhea, reflux, and indigestion decreased.

41 Delayed gastric emptying and bile reflux are common concerns in long-term survivors after

42 addition, extraesophageal manifestations of reflux are most effectively diagnosed with a stepwise ap

43 , digital ulceration, and gastro-oesophageal reflux, are now treatable.

44 No longitudinal studies of reflux-associated erosive tooth wear and of reflux chara

45 Gastroesophageal acid reflux at each of the pH sensors extending 5.5 cm proxim

46 egorized as (a) fully patent, minimal, or no reflux; (b) >50% patent but some reflux; (c) some patenc

47 exposure of esophageal cells to acidic bile reflux (BA/A).

48 s exposure arises via compromise of the anti-reflux barrier and reduced ability of the esophagus to c

49 symptoms also occur in the context of normal reflux burden, when there is either poor epithelial resi

50 w percentage of children have vesicoureteric reflux, but studies have suggested as many as 25-40% are

51 imal, or no reflux; (b) >50% patent but some reflux; (c) some patency but >50% reflux; or (d) nonpate

52 es suggest that inhibition of ROS induced by reflux can be a useful strategy for preventing DNA damag

53 reflux-associated erosive tooth wear and of reflux characteristics have been reported to date.

54 hloride and catalytic amounts of pyridine in refluxing chlorobenzene leads to the formation of acyl c

55 Though there was macroscopic bile reflux, clinical symptoms and microscopic changes were m

56 latory impedance testing underestimates acid reflux compared to esophageal acid exposure by discounti

57 Interestingly, under reflux conditions, the microwave-heated (MWH) reaction d

58 s that patients suffer from gastroesophageal reflux, constipation and delayed gastric emptying.

59 eflux disease (GERD) and may provide durable reflux control without fundoplication.

60 ociated with hemorrhage than cortical venous reflux (CVR) in patients with lateral sinus dural arteri

61 The outcome was recurrence of reflux, defined as use of antireflux medication (proton

62 The Gastrointestinal Symptom Rating Scale Reflux dimension was also improved for continuous versus

63 The presence of gastroesophageal reflux disease (26%), esophageal stricture (39%), or bot

64 0%), sinusitis (47.8%), and gastroesophageal reflux disease (46.3%).

65 e (NERD) compared with patients with erosive reflux disease (ERD) or Barrett's esophagus (BE).

66 e interval [CI], 2.9-12.9), gastroesophageal reflux disease (GERD) (RR, 1.9; 95% CI, 1.4-2.6), dyspep

67 thophysiological factor in gastro-esophageal reflux disease (GERD) and as a target for GERD treatment

68 ner to the understanding of gastroesophageal reflux disease (GERD) and its complications.

69 an alternative treatment of gastroesophageal reflux disease (GERD) and may provide durable reflux con

70 sophageal manifestations of gastroesophageal reflux disease (GERD) and to compare the most recent tec

71 urrent diagnostic tests for gastroesophageal reflux disease (GERD) are suboptimal and do not accurate

72 Management of gastroesophageal reflux disease (GERD) commonly starts with an empiric tr

73 d; 70% had been treated for gastroesophageal reflux disease (GERD) during infancy.

74 anges associated with acute gastroesophageal reflux disease (GERD) have not been studied prospectivel

75 r pH monitoring documented Gastro-Esophageal Reflux Disease (GERD) in 53.4% of patients.

76 as to compare recurrence of gastroesophageal reflux disease (GERD) in children randomized to laparosc

77 se or eliminate features of gastroesophageal reflux disease (GERD) in some patients whose symptoms pe

78 It has been suggested that gastroesophageal reflux disease (GERD) is a risk factor for developing rh

79 The pathogenesis of gastroesophageal reflux disease (GERD) is complex and involves changes in

80 Gastroesophageal reflux disease (GERD) is prevalent worldwide, particular

81 Gastro-esophageal reflux disease (GERD) is suggested to be associated with

82 Gastroesophageal reflux disease (GERD) is the most prevalent gastrointest

83 Gastroesophageal reflux disease (GERD) is the strongest known risk factor

84 The prevalence of gastro-esophageal reflux disease (GERD) varies widely around the world.

85 f objective measurements of gastroesophageal reflux disease (GERD) would improve management of patien

86 table bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and overactive bladder syndrome (

87 r three common indications: gastroesophageal reflux disease (GERD), Barrett's esophagus (BE), and non

88 Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and irr

89 tory drugs) and symptoms of gastroesophageal reflux disease (GERD).

90 r patients with early-stage gastroesophageal reflux disease (GERD).

91 ice for obese patients with gastroesophageal reflux disease (GERD).

92 r both BE and EA is chronic gastroesophageal reflux disease (GERD).

93 s omeprazole monotherapy in gastroesophageal reflux disease (GERD).

94 (CNF) for the treatment of gastroesophageal reflux disease (GERD).

95 o included 10 patients with gastroesophageal reflux disease (GERD; age, 32-60 y; 7 women) without tro

96 symptom control in patients with non-erosive reflux disease (NERD) after 6 months.

97 t symptom burden in patients with nonerosive reflux disease (NERD) compared with patients with erosiv

98 igated whether patients with supraesophageal reflux disease (SERD) have impaired UES and esophageal b

99 of peptic ulcer disease and gastrosophageal reflux disease and acts by irreversibly blocking ATP4A,

100 The incidence of gastro-oesophageal reflux disease and Barrett's oesophagus is increasing.

101 psies of patients with EoE, gastroesophageal reflux disease and controls.

102 ties is similar except for gastro-esophageal reflux disease and dyslipidemia that appear to be more s

103 both procedures except for gastro-esophageal reflux disease and dyslipidemia, which were more success

104 The potential roles of undiagnosed venous reflux disease and the military physical training enviro

105 n with a medical history of gastroesophageal reflux disease and type II diabetes presented to the hos

106 ation rate and incidence of gastroesophageal reflux disease are concerning.

107 nd has focused attention on gastroesophageal reflux disease as a causative factor in this shift.

108 of a confirmed diagnosis of gastroesophageal reflux disease by an abnormal esophageal pH study (body

109 that is distinguished from gastroesophageal reflux disease by the expression of a unique esophageal

110 rugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive drugs, sleep aids

111 sses (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, antihypertensive d

112 Most patients with gastroesophageal reflux disease experience symptomatic relapse after stop

113 c antireflux surgery due to gastroesophageal reflux disease in adults (>18 years).

114 cidic environment caused by gastroesophageal reflux disease in the gastroesophageal junction and asso

115 Gastroesophageal reflux disease is a highly prevalent disease.

116 Gastro-oesophageal reflux disease is a potential risk factor for the develo

117 orically distinguished from gastroesophageal reflux disease on the basis of histology and lack of res

118 vely high rate of recurrent gastroesophageal reflux disease requiring treatment, diminishing some of

119 De novo gastroesophageal reflux disease was reported in 43.8%.

120 eep-disordered breathing, gastro-oesophageal reflux disease, and anxiety or depression.

121 isk factor for oesophageal adenocarcinoma is reflux disease, and the rising incidence of this coincid

122 have been identified-mainly gastroesophageal reflux disease, Barrett's esophagus, obesity, and tobacc

123 e and effective therapy for gastroesophageal reflux disease, but its effect on the LES has not been e

124 Risk factors include gastroesophageal reflux disease, central obesity, and smoking.

125 , regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, laryngitis, GERD, GOR

126 , regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, laryngitis, GERD, GOR

127 l complications of obesity: gastroesophageal reflux disease, erosive esophagitis, Barrett's esophagus

128 ides a clinical overview of gastroesophageal reflux disease, focusing on diagnosis, treatment, and pr

129 ry of peptic ulcer disease, gastroesophageal reflux disease, or gastrointestinal bleeding, and prior

130 f non-drug treatments for gastro-oesophageal reflux disease, safety of long-term drug treatment, and

131 pertension, hyperlipidemia, gastroesophageal reflux disease, thyroid disease, diabetes, osteoporosis)

132 fied version of a validated gastroesophageal reflux disease-specific QOL tool to patients before and

133 ty of life, measured by the gastroesophageal reflux disease-specific QOL tool, and recurrence, define

134 ure by waist belt on reflux in patients with reflux disease.

135 o clear and buffer the refluxate, leading to reflux disease.

136 long-lasting treatment for gastroesophageal reflux disease.

137 to those of patients with gastro-oesophageal reflux disease.

138 evant to the association between obesity and reflux disease.

139 heartburn in patients with gastro-esophageal reflux disease.

140 ged period of mucosal contact with each acid reflux episode, particularly in the recumbent position.

141 ay not routinely account for duration of the reflux episode.

142 e studies as abnormal than MII-detected acid reflux episodes [42 vs 34 % (p < 0.01)].

143 ge of time with a pH < 4, the number of acid reflux episodes and the percentage of proximal esophagea

144 er one year, but the number of weakly acidic reflux episodes decreased significantly in the large sub

145 nce-pH testing (MII) allows for detection of reflux episodes regardless of pH.

146 -response relationship between the number of reflux episodes/week in 1999 and the risk of having NIR

147 reflux was defined by abnormal pH-testing or reflux esophagitis >Los Angeles grade A.

148 ts should be considered high risk to develop reflux esophagitis and advised of the management conside

149 se) or is a significant risk factor, such as reflux esophagitis and gallstones.

150 have challenged the traditional notion that reflux esophagitis develops when esophageal surface epit

151 se findings suggest that the pathogenesis of reflux esophagitis may be cytokine-mediated rather than

152 preliminary study of 12 patients with severe reflux esophagitis successfully treated with PPI therapy

153 llas Veterans Affairs Medical Center who had reflux esophagitis successfully treated with proton pump

154 verall, 5 % of the on-demand group developed reflux esophagitis versus none in the continuous group (

155 Reflux esophagitis was detected in 24 (45%), 17 (32%), a

156 Reflux esophagitis was seen in 17 cases (32.7%) of SSc a

157 hree events (drug inefficacy, gastritis, and reflux esophagitis) in two patients were considered rela

158 ht loss, GBP reduces GERD symptoms, improves reflux esophagitis, and decreases esophageal acid exposu

159 phincter (UES) and esophageal body to liquid reflux events prevent esophagopharyngeal reflux and its

160 Following the meal, the mean number of reflux events with the belt was 4, vs 2 without (P = .00

161 and esophageal responses to simulated liquid reflux events.

162 S and esophageal body responses to simulated reflux events.

163 Background acidic esophageal reflux exposure appeared stable over time, whereas weakl

164 se (GERD) is complex and involves changes in reflux exposure, epithelial resistance, and visceral sen

165 percritical CO2 (SC-CO2) extraction and heat-reflux extraction (HRE), conducted in parallel.

166 us, we found belt compression increased acid reflux following a meal.

167 dehydes in a cosolvent of toluene and THF at reflux for 10 h, and (ii) NaBH4 promoted regio- and ster

168 using a microwave process with acetonitrile reflux for 10 min.

169 cosolvent of toluene and HOAc (v/v = 1/1) at reflux for 3 h.

170 ation revealed that solution-based assembly (refluxing for days) results in the formation of large ol

171 istinguish extraesophageal manifestations of reflux from idiopathic chronic cough, laryngitis due to

172 duals with confirmed UTIs and vesicoureteral reflux from the Randomized Intervention for Children wit

173 Gastro-oesophageal reflux (GER) and microaspiration have been proposed as r

174 prevalence of abnormal acid gastroesophageal reflux (GER) is higher in patients with idiopathic pulmo

175 tooth wear have significant gastroesophageal reflux (GERD), despite minor reflux symptoms.

176 ) and Grubbs' catalyst (12-24 mol %, CH2Cl2, reflux) give the cage-like trienes trans- Fe(CO)3(P((CH2

177 Gastro-Oesophageal Reflux (GOR) is a key problem in Cystic Fibrosis (CF), b

178 sed by 47% when adjusting for vesicoureteral reflux grade and bowel and bladder dysfunction.

179 67 years or older (odds ratio [OR] = 4.46), reflux grade of 3 or higher (OR = 2.63), right atrial vo

180 Outcomes studied included reflux grade, UTIs during the study on placebo or antibi

181 esophageal pH monitoring documented abnormal reflux in 33 cases (80.5%) of SSc and no such abnormalit

182 number of investigations for vesicoureteric reflux in children who have had a febrile urinary tract

183 he further elucidation of the causal role of reflux in erosive tooth wear.

184 xcessive apoptosis leading to vesicoureteral reflux in newborns, which underscores the importance of

185 creasing abdominal pressure by waist belt on reflux in patients with reflux disease.

186 Microscopic bile reflux index (BRI) was calculated and a score more than

187 D, which was defined as GERD combined with a reflux index greater than 4 on pH monitoring and/or gast

188 Mean bile reflux index score was 9.7 (range 1.77-34).

189 Acid reflux-induced oesophagitis and the multilayered epithel

190 Acute biliary pancreatitis, caused by bile reflux into the pancreas, is a serious condition charact

191 udden and severe condition initiated by bile reflux into the pancreas.

192 us may be more suitable when early stasis or reflux is a concern, in the setting of hepatocellular ca

193 e laryngeal inflammation from smoking and/or reflux is commonly diagnosed as chronic laryngitis and t

194 Vesicoureteric reflux is defined as the retrograde passage of urine fro

195 ough, LPR, or asthma due to gastroesophageal reflux is difficult, as no criterion standard test exits

196 The management of vesicoureteral reflux is evolving, with advocacy ranging from a less in

197 n (UTI) risk in children with vesicoureteral reflux is largely unknown.

198 management of patients suspecting of having reflux, leading to rational selection of treatment and b

199 from donor-directed Abs or gastroesophageal reflux led to new ColV and KAT Abs post respiratory vira

200 ons of GERD include cough, laryngopharyngeal reflux (LPR), and asthma.

201 tations of reflux, specifically cough due to reflux, LPR, and asthma due to reflux.

202 The mechanisms whereby bile acid reflux may accelerate the progression from Barrett's eso

203 However impedance-based diagnosis of reflux may not routinely account for duration of the ref

204 in 30min compared to 16h by the conventional reflux method (P<0.05).

205 Prolonged biliary reflux might be the most important risk factor of gastri

206 study is to review the literature on the rat reflux model in an effort to elucidate this phenomenon.

207 The rat reflux model is a validated reproducible model for the d

208 y of esophageal adenocarcinoma using the rat reflux model.

209 e or 6,6'-dimethoxy-5,5'-binaphthoquinone in refluxing nitrobenzene (210 degrees C) gives, in a singl

210 ultaneously interacting with gastresophageal reflux, obesity, and tobacco smoking with genome-wide si

211 is, chronic rhinosinusitis, gastroesophageal reflux, obstructive sleep apnoea, vocal cord dysfunction

212 ent esophageal adenocarcinoma in humans, the reflux of an admixture of acid and bile must be controll

213 Esophageal reflux of an admixture of gastric acid and duodenal juic

214 As in the rat so also in humans, reflux of an admixture of gastric acid and duodenal juic

215 Significant reflux of N-(11)C-methyl-taurolithocholic acid into the

216 sensitive than pH-testing in detecting acid reflux off therapy as a result of discounting duration o

217 es and the percentage of proximal esophageal reflux off-PPI did not change significantly after one ye

218 nd 184 of 1354 men [13.6%] had recurrence of reflux), older age (HR, 1.41 [95% CI, 1.10-1.81] for age

219 roved symptoms of watering and minimal or no reflux on nasolacrimal syringing.

220 y improved with a combination of patency and reflux on syringing.

221 r worse symptoms of watering and 50% to 100% reflux on syringing.

222 39 families with nonsyndromic vesicoureteric reflux, only one carried a putative pathogenic HPSE2 var

223 om 360 (48%) had dysphagia and 390 (52%) had reflux or other symptoms.

224 ents with IPF, in the absence of oesophageal reflux or symptoms.

225 t but some reflux; (c) some patency but >50% reflux; or (d) nonpatent, 100% reflux.

226 Baseline characteristics and reflux parameters of MII studies performed off-anti-secr

227 Findings of abnormal reflux persist in a large proportion of patients with IP

228 not been investigated in the vesicoureteral reflux population.

229 ng endothelial transfer constant (K(trans)), reflux rate (Kep), fractional extravascular extracellula

230 ion columns in batch distillation with fixed reflux rate are useful to obtain distillates or distilla

231 s have shown that a drastic reduction of the reflux rate at an early stage of the heart cut produced

232 (ADC), volume transfer constant (K(trans)), reflux rate constant (kep), and area under the gadoliniu

233 This study explores variable reflux rate operating strategies to increase the levels

234 flux surgery was not associated with risk of reflux recurrence (HR, 1.09 [95% CI, 0.77-1.53] for hosp

235 and interviews, have reported high rates of reflux recurrence after antireflux surgery, which may ha

236 Reflux recurrence after laparoscopic antireflux surgery

237 To determine the risk of reflux recurrence after laparoscopic antireflux surgery

238 Risk factors for reflux recurrence included female sex (hazard ratio [HR]

239 gression was used to assess risk factors for reflux recurrence.

240 edian of 5.6 years, 470 patients (17.7%) had reflux recurrence; 393 (83.6%) received long-term antire

241 Early surgical intervention to prevent reflux reduces the progression toward esophageal adenoca

242 include potassium-competitive acid blockers, reflux-reducing agents, bile acid binders, injection of

243 e biopsies should be repeated after the anti-reflux regimen has been further intensified.

244 17.7% experienced recurrent gastroesophageal reflux requiring long-term medication use or secondary a

245 re hypotonia, pathological gastro-esophageal reflux, retinal disease, and sinus-node dysfunction, whe

246 ntervention for Children with Vesicoureteral Reflux (RIVUR) Study and 295 controls, and we correlated

247 Gastroesophageal reflux scores were higher in overweight/obese children (

248 d in terms of yield and purity: conventional reflux, sealed vessel heated in an oil bath, and microwa

249 eatment of extraesophageal manifestations of reflux, specifically cough due to reflux, LPR, and asthm

250 edicted FEV1, self-reported gastroesophageal reflux, St. George's Respiratory Questionnaire score, sm

251 Reflux status did not affect microbial diversity nor com

252 ntervention for Children With Vesicoureteral Reflux Study, a 2-year randomized clinical trial that en

253 Although the reflux subscore improved in both groups, it was worse in

254 dysmorphism, strabismus, and vesicoureteric reflux, suggesting that EBF3 has a widespread developmen

255 ventral incisional hernia repair, colectomy, reflux surgery, bariatric surgery, and hysterectomy).

256 but was also present in those referred with reflux symptoms (64 [19%] of 329 patients vs 32 [10%] pa

257 fied Rome III criteria) and gastroesophageal reflux symptoms (GERS) in a population-based follow-up s

258 t with dysphagia, chest pain, and refractory reflux symptoms after an endoscopy does not reveal a mec

259 s comprising 463 controls with dyspepsia and reflux symptoms and 647 BE cases swallowed a Cytosponge

260 azole alone in providing complete cupping of reflux symptoms and healing of esophagitis in patients w

261 ents in group 2 demonstrated full cupping of reflux symptoms at 8 weeks.

262 le in management of patients with persistent reflux symptoms despite adequate medical or surgical tre

263 (>/=3 episodes of nocturnal gastroesophageal reflux symptoms per week) had an OR of 1.6 (95% CI 1.0-2

264 expensive approach to identify patients with reflux symptoms who warrant endoscopy to diagnose BE.

265 Data regarding the presence of reflux symptoms, dysphagia, general health, PPI use, and

266 g 98 (44%) with dysphagia and 123 (56%) with reflux symptoms.

267 astroesophageal reflux (GERD), despite minor reflux symptoms.

268 ears to be partially mediated via esophageal reflux symptoms.

269 Typical reflux syndrome displayed a significant decrease from 31

270 H2O2 was performed in a digester block with reflux system and heated at 200 degrees C for 150min.

271 ng palladium on charcoal in diphenylether at reflux temperature.

272 but moderate to good yields are obtained at refluxing temperatures.

273 Reflux therefore develops via alterations in the balance

274 lated compounds employing K2CO3 as a base in refluxing THF and DMF at 80 degrees C, respectively, del

275 attribute exertional dyspnea and esophageal reflux to asthma, leading to excess rescue medication us

276 mediate progression of chronic acid biliary reflux to Barrett's esophagus and cancer.

277 inoma (EA) led to screening of patients with reflux to detect Barrett's esophagus (BE) and surveillan

278 es with a catalytic amount of strong acid in refluxing toluene affords the corresponding dihydrofuran

279 mido derivative with triphenyltin radical in refluxing toluene engenders a contact ion-pair (radical

280 The use of Rh2(Piv)4 in refluxing toluene results in the formation of 1,2-dihydr

281 tal catalyst; instead the addition occurs in refluxing toluene without additives.

282 ripyrrane, followed by oxidation with DDQ in refluxing toluene, gave carbaporphyrin or carbachlorin p

283 ntervention for Children With Vesicoureteral Reflux trial and the Careful Urinary Tract Infection Eva

284 Vesicoureteric reflux (VUR) is the commonest urological anomaly in chil

285 acute pyelonephritis (APN) or vesicoureteral reflux (VUR) using the data of 288 patients.

286 had combined reflux [acidic + weakly acidic reflux (WAR)].

287 The rate of gastroesophageal reflux was comparable with prior studies of both POEM an

288 Gastroesophageal reflux was defined by abnormal pH-testing or reflux esop

289 All underwent gastroscopy and bile reflux was grouped as normal, yellowish bile lakes and p

290 Objective evidence of reflux was present in 40% for all patients and 33% for p

291 Chronic sinusitis and gastroesophageal reflux were also associated with exacerbation frequency

292 eased by the belt, but those associated with reflux were increased (2 vs 3.5; P = .04).

293 roup B) had diagnosis of GERD: 23 had acidic reflux, whereas 9 had combined reflux [acidic + weakly a

294 PPIs) are popular drugs for gastroesophageal reflux, which are now available for long-term use withou

295 S: Central obesity promotes gastroesophageal reflux, which may be related to increased intra-abdomina

296 demonstrate that preventing gastroesophageal reflux with antireflux surgery halts the progression of

297 ge the anatomy of the foregut organs to stop reflux with minimal success.

298 he majority of patients with IPF have silent reflux with no symptoms of GER.

299 When refluxing with sodium hydrogen carbonate in acetonitrile

300 s performed with a 0.05 M ketone solution in refluxing xylene in the presence of 10 equiv of potassiu